Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Accounts Payable & Accrued Expense : $30.00 Mil (As of Mar. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals Accounts Payable & Accrued Expense?

Spectrum Pharmaceuticals's quarterly accounts payable & accrued expense declined from Sep. 2022 ($48.87 Mil) to Dec. 2022 ($38.84 Mil) and declined from Dec. 2022 ($38.84 Mil) to Mar. 2023 ($30.00 Mil).

Spectrum Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2020 ($51.60 Mil) to Dec. 2021 ($51.95 Mil) but then declined from Dec. 2021 ($51.95 Mil) to Dec. 2022 ($38.84 Mil).

Spectrum Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Spectrum Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals Accounts Payable & Accrued Expense Chart

Spectrum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

71.62

43.83

51.60

51.95

38.84

Spectrum Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															38.21	40.33	48.87	38.84	30.00

Spectrum Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110

Website

https://www.sppirx.com

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.

Executives

Juhyun Lim	director	11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick	director	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan	officer: See Remarks	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan	officer: Chief Legal Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga	director, officer: CEO & President	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel	officer: Chief Medical Officer	4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas	director	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson	officer: EVP & Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon	officer: Chief Commercial Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner	director	157 TEHCNOLOGY DRIVE, IRVINE CA 92618